Summary
- Current Price
- As of today, RPRX price is $68.05, up +0.73% in the most recent trading session on
- Current Price All-Time High
- RPRX price is currently -2.35% below its historical high of $69.69 set on an earlier date
- Market Cap
- RPRX current market cap is $39B, up +126.75% over the past 365 days
- PE Ratio
- RPRX current PE ratio is 36.23
- Revenue
- RPRX current annual revenue is $2.38B, up +5.06% year-over-year
- Next Earnings
- As of today, the next earnings release for RPRX has not been scheduled
Profile
| Metric | Value |
|---|---|
| Full Name | Royalty Pharma plc |
| Ticker | NASDAQ: RPRX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | royaltypharma.com |
| Employees | 100 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $68.05 | |
| Price, 1D Change | +0.73% | |
| Market Cap | $39B | |
| TTM Dividend Yield | 1.36% | |
| PE Ratio | 36.23 | |
| Beta | 0.22 | |
| Revenue | $2.38B | |
| Revenue, 1Y Change | +5.06% | |
| EPS | $1.78 | |
| EPS, 1Y Change | -6.83% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | N/A | |
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.24 | |
| Next Ex-Dividend | $0.24 | |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $1.78 | |
| EPS Estimate | $5.32 | N/A |
| EPS Est. Change | +198.72% | N/A |
| Revenue | $2.38B | |
| Revenue Estimate | $3.51B | N/A |
| Revenue Est. Change | +47.40% | N/A |
| Current Price | $68.05 | |
| Price Target | $66.00 | - |
| Price Tgt. Change | -3.01% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.05 | $1.91 | -52.78% | |
| $4.64 | $1.78 | -61.59% | |
| $5.32 | N/A | +198.72% | |
| $5.81 | N/A | +226.09% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.70B | $2.26B | -16.32% | |
| $3.21B | $2.38B | -25.99% | |
| $3.51B | N/A | +47.40% | |
| $3.82B | N/A | +60.81% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +68.36% | |
| Price, 3Y | +143.47% | |
| Market Cap, 1Y | +126.75% | |
| Market Cap, 3Y | +215.55% | |
| Revenue, 1Y | +5.06% | |
| Revenue, 3Y | +6.30% | |
| EPS, 1Y | -6.83% | |
| EPS, 3Y | +1,721.47% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $68.05 | |
| SMA 200 | $53.63 | |
| SMA 50 | $60.59 | |
| EMA 200 | $54.11 | |
| EMA 50 | $61.07 | |
| MACD | $2.21 | |
| Beta | 0.22 | |
| ATR | $1.47 | |
| 14-Day RSI | 74.41 | |
| 10-Day Volatility | 19.23% |
Dividends
| Metric | Value | Date |
|---|---|---|
| Last Paid | $0.24 | |
| Upcoming | $0.24 | |
| Dividend Yield | 1.29% | |
| Total Dividend | $0.88 | |
| $378.25M | ||
| 28.56% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $2.38B | |
| EPS | $1.78 | |
| Gross Profit | $2.37B | |
| Gross Margin | 99.84% | |
| Operating Income | $1.56B | |
| Operating Margin | 65.58% | |
| Net Income | $1.32B | |
| Net Margin | 55.68% | |
| EBITDA | $1.56B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 1.38 | |
| 2.40 | ||
| 2.40 | ||
| - | ||
| 6 | ||
| 2.99 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 36.23 | |
| 15.51 | ||
| 5.75 | ||
| 29.92 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $6.48B | |
| $637.50M | ||
| $19.62B | ||
| $1.53B | ||
| $9.91B | ||
| $636.21M | ||
| Total Debt | $8.97B | |
| $380.00M | ||
| $19.40M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $1.61B | ||
| $814.82M | ||
| $3.85M | ||
| $0.00 | ||
| $3.85M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $2.59B | ||
| -$1.71B | ||
| -$1.19B | ||
| Capex | $1.70B | |
| $897.24M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Morgan Stanley | → | |
| TD Cowen | → | |
| JP Morgan | → | |
| TD Cowen | → | |
| JP Morgan | → | |
| Citigroup | → | |
| UBS | → | |
| Morgan Stanley | → | |
| UBS | → | |
| Citigroup | → |
Analyst sentiment
Institutional ownership
Screeners with RPRX
FAQ
- What is the ticker symbol for Royalty Pharma plc?
- The ticker symbol for Royalty Pharma plc is NASDAQ:RPRX
- Does Royalty Pharma plc pay dividends?
- Yes, Royalty Pharma plc pays dividends. The last payment was $0.24, with an ex-dividend date on August 14, 2026
- What sector is Royalty Pharma plc in?
- Royalty Pharma plc is in the Healthcare sector
- What industry is Royalty Pharma plc in?
- Royalty Pharma plc is in the Biotechnology industry
- What country is Royalty Pharma plc based in?
- Royalty Pharma plc is headquartered in United States
- When did Royalty Pharma plc go public?
- Royalty Pharma plc initial public offering (IPO) was on June 16, 2020
- Is Royalty Pharma plc in the S&P 500?
- No, Royalty Pharma plc is not included in the S&P 500 index
- Is Royalty Pharma plc in the NASDAQ 100?
- No, Royalty Pharma plc is not included in the NASDAQ 100 index
- Is Royalty Pharma plc in the Dow Jones?
- No, Royalty Pharma plc is not included in the Dow Jones index
- When was Royalty Pharma plc last earnings report?
- Royalty Pharma plc's most recent earnings report was on November 4, 2026
- When does Royalty Pharma plc report earnings?
- The date for Royalty Pharma plc's next earnings report has not been announced yet
Data Sources & References
- RPRX Official Website www.royaltypharma.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1802768/000180276826000003/0001802768-26-000003-index.htm
- RPRX Profile on Yahoo Finance finance.yahoo.com/quote/RPRX
- RPRX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rprx
